ImThera Gets Go-Ahead For Sleep Apnea Nerve Stimulator Pivotal Study
This article was originally published in The Gray Sheet
Executive Summary
The aura6000 sleep apnea system has received investigational device exemption approval for a pivotal trial but still lags behind key rival Inspire Medical Systems Inc.’s Inspire upper airway stimulator.
You may also be interested in...
UK Health Service Not Taking Full Advantage Of Digital Self-Care Apps – PAGB Audit
PAGB calls on NHS England to create a self-care section in its NHS App and reinstate its online Apps Library to promote responsible digital self-care in the UK.
ADCs Propel China Oncology Innovation But PD-1s Still Cast Shadow
Among the newer modalities to tackle cancer, antibody-drug conjugates are fast emerging to rival targeted antibodies and China is fast emerging as a world class source of innovation in the field, as evidenced by a string of recent deals.
Ionis Closer To First Wholly-Owned Drug Launch With Olezarsen Phase III Success
Ionis will seek US and EU approvals to treat familial chylomicronemia syndrome in the first half of 2024. Phase III data in the larger severe hypertriglyceridemia indication are due in late 2024 or early 2025.